Helicobacter pylori Therapy in Latin America: Triple-Drug Regimen Still Best

Standard 14-day triple-drug therapy — despite its suboptimal eradication rate — was more effective than shorter-duration concomitant or sequential four-drug regimens.

Helicobacter pylori eradication rates with standard triple therapy are decreasing in Europe and Asia because of antibiotic resistance. Little research has been done to determine the optimal therapeutic regimen in Latin America, where H. pylori infection is endemic and antibiotic resistance patterns might be different. Now, investigators have conducted an open trial at seven sites in Latin America to compare the effectiveness of three treatments.

Potentially eligible adults were recruited from the general population; H. pylori infection was confirmed using a urea breath test. A total of 1463 participants were randomized to receive one of three therapy regimens using generic drugs:

Standard (14 days of triple therapy with lansoprazole, amoxicil…

Reviewing Author

David J. Bjorkman, MD, MSPH (HSA), SM (Epid.)

Disclosures

Nothing to disclose

David J. Bjorkman, MD, MSPH (HSA), SM (Epid.)

Disclosures

Nothing to disclose

Helicobacter pylori Therapy in Latin America: Triple-Drug Regimen Still Best

Topics

Reviewing Author